Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 139Breast Neoplasms 31Prostatic Neoplasms 29Insulin Resistance 28Obesity 19Pancreatic Neoplasms 13Neoplasms 12Infertility 12Endometrial Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Colorectal Neoplasms 11Anovulation 9Lung Neoplasms 8Metabolic Syndrome 7Melanoma 7Hyperandrogenism 7Glioblastoma 7Diabetes Mellitus 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Rectal Neoplasms 5Adenocarcinoma 5Weight Loss 4Urinary Bladder Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Head and Neck Neoplasms 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Uterine Cervical Neoplasms 3Recurrence 3

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡